Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments

The proceedings failed to conscionable an interim progression-free endurance threshold, expanding capitalist doubts regarding its efficacy successful examination to information from HARMONi-6, a China-exclusive trial.

Cantor Fitzgerald reported that aesculapian professionals were little deterred by the interim progression-free endurance shortfall. The adept sentiment was influenced by the firm’s debased alpha walk and the information that the investigation was performed precise early.

Meanwhile, H.C. Wainwright downgraded Summit Therapeutics Inc. (NASDAQ:SMMT) to Neutral from Buy, noting contention from Merck’s sacituzumab tirumotecan results. The steadfast stated that sacituzumab tirumotecan, coupled with pembrolizumab, had an immature wide endurance hazard ratio of 0.55, which mightiness spot strain connected Summit’s ivonescimab if the inclination continues with prolonged follow-up.

Summit Therapeutics Inc. (NASDAQ:SMMT) is simply a biopharmaceutical firm. The company’s main product, Ridinilazole, is an orally administered small-molecule antibiotic present successful Phase III objective trials to dainty CDI.

While we admit the imaginable of SMMT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.